Stifel Nicolaus Reaffirms Their Buy Rating on OptimizeRx (OPRX)

In a report released today, David Grossman from Stifel Nicolaus maintained a Buy rating on OptimizeRx (OPRX – Research Report), with a price target of $13.00. The company’s shares closed yesterday at $10.48.

Grossman covers the Technology sector, focusing on stocks such as Accenture, Epam Systems, and Infosys. According to TipRanks, Grossman has an average return of 7.3% and a 55.65% success rate on recommended stocks.

In addition to Stifel Nicolaus, OptimizeRx also received a Buy from JMP Securities’s Constantine Davides in a report issued today. However, on the same day, Barclays maintained a Hold rating on OptimizeRx (NASDAQ: OPRX).

The company has a one-year high of $16.65 and a one-year low of $6.92. Currently, OptimizeRx has an average volume of 137.2K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

OptimizeRx (OPRX) Company Description:

OptimizeRx Corp. engages in the provision of digital health messaging via electronic health records, which serves as a direct channel for pharmaceutical companies to communicate with healthcare providers. It offers EHR workflow solutions which include financial messaging, patient education, and brand messaging; and brand support. The company was founded by David A. Harrell on November 8, 1985 and is headquartered in Rochester, MI.